Phase III DeLLphi-304 results show T-cell engager Imdelltra (tarlatamab) delivers superior overall survival, improved ...

As stakeholders debate fair market value in clinical trial budgeting, a new task force works to align sponsors, CROs, and ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Case study highlights how clinical operations teams can overcome complex regulatory and operational hurdles to finish a trial ...

In this video interview, Jim Kremidas, executive director, Association for MultiSite Research Corporations (AMRC), discusses ...

Phase II CONFIDENCE study data reveal that simultaneous initiation of Kerendia and Jardiance significantly improves UACR and ...

New data from the IRAKLIA and IZALCO trials, presented at the 2025 ASCO Annual Meeting, demonstrate that subcutaneous ...

Results from the Phase Ib/II CARTITUDE-1 trial demonstrated that a single infusion of Carvykti delivered durable, ...

In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

As biotech innovation accelerates, the clinical research workforce is rapidly eroding—threatening the future of drug ...

In this video interview, Jim Kremidas, executive director, Association for MultiSite Research Corporations (AMRC), talks ...

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi ...